Loading
A phase 1/2 trial of Mavrostobart, Tislelizumab, Gemcitabine in non-small-cell lung cancer and small-cell lung cancer, run by Phanes Therapeutics, now recruiting.
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) is a phase 1/2 interventional study registered as NCT05431270 by Phanes Therapeutics, with 40 participants planned, started 2022-08-11 and due to reach its primary completion in 2027-12. Interventions recorded: Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed. Conditions listed: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Phanes Therapeutics, Paclitaxel / nab-paclitaxel, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma.
Shares Tislelizumab, Pemetrexed, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
Shares Pemetrexed, Docetaxel, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
Shares Pemetrexed, Docetaxel, Paclitaxel / nab-paclitaxel, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/